Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-12-07
2003-11-18
Lilling, Herbert J. (Department: 1651)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C424S725000, C424S769000, C424S770000, C514S468000, C514S473000
Reexamination Certificate
active
06649650
ABSTRACT:
FIELD OF INVENTION
The present invention relates to a novel herbal composition for the treatment of cancer. The present invention particularly relates to an herbal formulation comprising mixture of lignans isolated from the plant
Cedrus Deodara.
BACKGROUND OF INVENTION
Cancer or neoplasm is the malignant new growth anywhere and elsewhere in the body system. It is characterized by unregulated proliferation of cells and a growing public health problem whose estimated worldwide new incidence is about six million cases per year. In most of the countries, cancer is second only to heart disease as cause of death. It can arise in any organ of the body but some sites are prone to attack than others such as breast, throat, intestine, leukocytes etc. Each cancer is propagated from a single cell that cut at some stage, it becomes free from its territorial restraints, which form a family of cells that multiply without limits and appear in the form of tumors.
During the transition from normal cell to a tumor cell a profound and heritable change occurs which allows a tumor cell to determine its own activities largely irrespective of the laws that govern so precisely the growth of all normal cells in an organism. This newly acquired property, which is known as autonomy, is the most important single characteristic of tumor cells since without it there would be no tumors. Another distinguishing characteristic of tumor cells is their lack of perfect form of function. The differences that exist between cancer and normal cells are that, compared to normal cells, cancer cells have a) low pH b) greater free radical character c) tumor produced hormone peptides d) tumor associated antigens e) lower calcium ion and higher potassium ion concentration f) different potassium isotope ratios g) elevated amounts of methylated nucleotides h) higher concentrations of plasma microproteins and mucopolysacharides i) greater need of exogenous zinc and j) high biowater content.
Many of the gross causes of cancer, such as dietary, environmental, occupational exposure to certain chemical substances or forms of electromagnetic radiation, have been elucidated through epidemiological studies. It is imperative, therefore, that they be identified and eliminated from the environment in so far as that is possible in modern industrial societies. In the annals of therapy, a quest to conquer, the impasse of cancer has been always fascinated by and large all disciplines of scientific community, especially natural product chemists. In 19
th
and 20
th
century, lot of research work has been carried out to find out the driving force behind this dreadful disease as well as large number of drugs have been introduced to counter its menace.
It is worthwhile at this juncture to look briefly at a few most powerful chemotherapeutic agents, which have been of paramount importance to the mankind and also to the researchers who have been actively involved in the synthesis and isolation of anticancer drugs. Lignans have been isolated from a number of plants (Achenbach, H., Waibel, R. and Meusah, I.
Phytochemistry,
22 (3), 749-753 (1983); Nishibe, S., Hisada, S. and Inagaki, I.
Phytochemistry,
10, 2231-2232 (1971); Barrero, A. F., Haidour, A. and Dorado, M. M.
J. Nat. Prod.
42,159-162(1979)).
Recent studies on the biological activities of lignans prove beyond doubt the efficacy of these phytochemicals as cytotoxic agents (Macrae, W. D. and Towers, G. H. N.
Phytochemistry
23 (6), 1207-1220 (1984)). Also recently lignans have been isolated from human urine and blood. This fact also suggests that lignans are playing a definite role in human physiology.
With the above background, the applicants have focussed their attention towards the identification and isolation of potent cytotoxic agents from plants. Literature data suggests the presence secoisolariciresinol in
Cedrus deodara
(Agarwal, P. K. and Rastogi, R. P.
Phytochemistry,
21 (6), 1459-1461 (1982)) which is in all likelihood may be an artefact, is a proven antioxidant. Further investigation on
Cedrus Deodara
carried out by us led us to the isolation of a new lignan mixture comprising essentially (−)-Matairesinol, (−)-Wikshtronol and Dibenzyl butyrolactol in an extremely significant yield,
Cedrus deodara
is also a new source for these lignans.
(−)-Wikstromol was first reported from
wikstroemia viridiflora
(Nishibe, S., Hisada, S. and Inagaki, I.
Phytochemistry,
10, 2231-2232 (1971)). Matairesinol was isolated from a number of sources before (Nishibe, S., Hisada, S. and Inagaki, I.
Phytochemistry,
10, 2231-2232 (1971); Tandon, S. and Rastogi, R. P. Phytochemistry, 15, 1789-1791 (1976)). The isolation of the dibenzylbutyrolactol [4,4′,9-trihydroxy-3,3′-dimethoxy-9,9′-epoxy lignan] was reported only once previously from the wood of
Abies pinsapo
(Barrero, A. F., Haidour, A. and Dorado, M. M.
J. Nat. Prod.
42, 159-162 (1979)).
Keeping in mind the high yields of the lignans from
Cedrus deodara
and also the excellent biological activities and lignans in general (Macrae, W. D. and Towers, G. H. N.
Phytochemistry
23(6), 1207-1220 (1984).
OBJECTS OF THE INVENTION
Main object of the invention relates to herbal compositions for the treatment of human cancer cells.
Another object of the invention relates to herbal compositions for the treatment of human cancer cells obtained from a plant source.
Another object of the invention relates to in-vitro cytotoxicity of lignan mixtures isolated from
Cedrus deodara
against various human cancer cell lines.
Still another object of the invention relates to cytotoxicity of individual lignans isolated from
Cedrus deodara
against various human cancer cell lines.
Still another embodiment of the invention relates to a method of isolation of the active lignan mixture from the plant source namely
Cedrus deodara.
Yet another object of the invention relates to a synergistic lignan composition obtained from plant
Cedrus deodara
for inhibiting the growth of human cancer cells.
Yet another object of the invention relates to a composition comprising individual lignans isolated from plant
Cedrus deodara
for inhibiting the growth of human cancer cells.
Yet another embodiment relates to method of treating mammals, particularly human beings affected by cancer.
SUMMARY OF THE INVENTION
Accordingly, the present invention provides a novel synergistic composition of lignans exhibiting anticancer activities for breast, cervix, neuroblastoma, colon, liver, lung, mouth, ovary and prostate cancer obtained from the plant extract of
Cedrus deodra
, said composition comprising_of
(a) (−) -Matairesinol in the range of 9 to 13% by weight,
(b) (−) -Wikstromol in the range of 75 to 79% by weight,
(c) Dibenzylbutyrolactol in the range of 7 to 11% by weight, and
(d) Unidentified material in the range of 2.6 to 3% by weight,
Further, the synergistic composition of lignan may be used in combination with pharmaceutically acceptable carriers for inhibiting various human cancer cell lines.
DETAILED DESCRIPTION OF THE INVENTION
An attempt is made to establish anticancer activity to the lignan mixture isolated from
Cedrus deodara
. The individual constituents isolated from the chloroform extract of
Cedrus deodara
wood have shown lesser level of activity compared to the lignan mixture establishing the principle of synergy.
Accordingly, the present invention provides a novel synergistic composition of lignans exhibiting anticancer activities for breast, cervix, neuroblastoma, colon, liver, lung, mouth, ovary and prostate cancer obtained from the plant extract of
Cedrus deodra
, said composition comprising_of
(e) (−) -Matairesinol in the range of 9 to 13% by weight,
(f) (−) -Wikstromol in the range of 75 to 79% by weight,
(g) Dibenzylbutyrolactol in the range of 7 to 11% by weight, and
(h) Unidentified material in the range of 2.6 to 3% by weight,
In another embodiment, wherein the synergistic lignans composition inhibits the growth of cancer cells of breast up to 80% at a concentration ran
Kampasi Himani
Qazi Gulam Nabi
Raghavan Kondapuram Vijaya
Rao Janaswamy Madhusudana
Saxena Ajit Kumar
Council of Scientific and Industrial Research
Lilling Herbert J.
Merchant & Gould P.C.
LandOfFree
Herbal chemical composition for the treatment of cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Herbal chemical composition for the treatment of cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Herbal chemical composition for the treatment of cancer will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3158344